Prevention of bleeding after percutaneous biopsy with a small intestinal submucosa hemostatic plug.

Coagulopathy Hemorrhage, porcine animal model Hemostatic plug Percutaneous biopsy Small intestinal submucosa Transplant-discarded human liver model

Journal

Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 28 08 2017
revised: 04 10 2021
accepted: 14 10 2021
pubmed: 24 10 2021
medline: 27 1 2022
entrez: 23 10 2021
Statut: ppublish

Résumé

Percutaneous biopsies (PBs) are the gold standard diagnostic procedures indicated for renal and hepatic disorders. Nevertheless, they can cause hemorrhages and are contraindicated for coagulopathic patients. In this study we designed, fabricated, and evaluated a small intestinal submucosa (SIS) plug to reduce, and potentially cease, bleeding to decrease death risk after percutaneous hepatic and renal biopsies in healthy and coagulopathic in vivo models. First, the plug's blocking capacity was determined with an increase in its diameter of 24 ± 11% after immersion in human blood, and the capacity to induce clotting on its surface. The plug's in vivo performance was evaluated in a healthy porcine model, which showed minimal inflammatory reaction without side effects confirmed by histological results after 30 days. The plug's response in the coagulopathic model was assessed using heparinized swine for 2 days, which revealed localized microhemorrhages and mild inflammatory response without any lesions to the surrounding tissue. No major adverse events nor macroscopic hemorrhages were detected in the animal models. Furthermore, we assessed the plug's efficacy to reduce and stop bleeding using a transplant-discarded human liver model (n = 14). In this case, the mass of blood lost was 43.8 ± 21.8% lower in plugged transplant-discarded human liver biopsies compared to control biopsies without a plug. The bleeding was stopped within three minutes in 92% of plugged cases, but only in 8% of non-plugged cases. We demonstrated the feasibility of making a hemostatic SIS plug, which does not induce major inflammatory reaction and can effectively reduce and stop bleeding after PBs in non-coagulopathic and coagulopathic in vivo models, and in a transplant-discarded human liver model. STATEMENT OF SIGNIFICANCE: Percutaneous biopsy (PB) is a gold standard diagnostic procedure, but it can provoke life-threatening complications and is contraindicated for patients with coagulopathic disorders. This study demonstrates that small intestinal submucosa (SIS) can be manufactured into a biocompatible thrombogenic plug, insertable through a commercial Tru-Cut needle sheath. This device takes advantage of the collagen-rich composition of SIS to stop and reduce bleeding more effectively than the traditional PB, indicating that it could be routinely employed in a traditional biopsy to increase safety, or as a cost and time-reducing alternative to transjugular biopsy for coagulopathic patients.

Identifiants

pubmed: 34687955
pii: S1742-7061(21)00693-0
doi: 10.1016/j.actbio.2021.10.025
pii:
doi:

Substances chimiques

Hemostatics 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-111

Informations de copyright

Copyright © 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Mateo Pineda (M)

Department of Biomedical Engineering, Universidad de los Andes, Colombia. Electronic address: m.pineda455@uniandes.edu.co.

Laura Lorena Cárdenas (LL)

Department of Biomedical Engineering, Universidad de los Andes, Colombia.

Javier Navarro (J)

Department of Biomedical Engineering, Universidad de los Andes, Colombia; Fischell Department of Bioengineering, University of Maryland, United States.

Diana Marcela Sánchez-Palencia (DM)

Department of Biomedical Engineering, Universidad de los Andes, Colombia.

Rocío Del Pilar López-Panqueva (RDP)

Department of Biomedical Engineering, Universidad de los Andes, Colombia; Department of Pathology, Hospital Universitario Fundación Santa Fe de Bogotá, Colombia.

Juan Manuel Pérez (JM)

Department of Radiology and Diagnostic Imaging, Fundación Cardioinfantil - Instituto de Cardiología, Colombia.

Juan Carlos Briceño (JC)

Department of Biomedical Engineering, Universidad de los Andes, Colombia; Research Department Fundación Cardioinfantil - Instituto de Cardiología, Colombia. Electronic address: jbriceno@uniandes.edu.co.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH